首页> 美国卫生研究院文献>Case Reports in Critical Care >Icatibant in the Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
【2h】

Icatibant in the Treatment of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema

机译:伊卡替班治疗血管紧张素转换酶抑制剂引起的血管性水肿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We describe the case of a 75-year-old woman who presented with massive tongue and lip swelling secondary to angiotensin-converting enzyme inhibitor-induced angioedema. An awake fibre-optic intubation was performed because of impending airway obstruction. As there was no improvement in symptoms after 72 hours, the selective bradykinin B2 receptor antagonist icatibant (Firazyr) was administered and the patient's trachea was successfully extubated 36 hours later. To our knowledge this is the first documented case of icatibant being used for the treatment of angiotensin-converting enzyme inhibitor-induced angioedema in the United Kingdom and represents a novel therapeutic option in its management.
机译:我们描述了一个75岁的女人的情况,该女人出现继发于血管紧张素转换酶抑制剂诱导的血管性水肿的大量舌头和嘴唇肿胀。由于即将发生气道阻塞,进行了清醒的光纤插管。由于72小时后症状没有改善,因此给予选择性缓激肽B2受体拮抗剂icatibant(Firazyr),并在36小时后成功拔除患者的气管。据我们所知,这是英国第一个有文献记载的依卡替班用于治疗血管紧张素转换酶抑制剂引起的血管性水肿,在其管理中代表了一种新颖的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号